| Ytd | -22.05% | |
| 1y | -17.26% |
| Open | 23.98 | Prev Close | 23.95 | Low | 23.98 | High | 25.20 | Mkt Cap | 1.60B |
| Vol | 918.96K | Avg Vol | 855.13K | EPS | -3.38 | P/E | N/A | Forward P/E | -7.04 |
| Beta | 1.26 | Short Ratio | 13.74 | Inst. Own | 125.34% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-03 | 50-d Avg | 29.51 | 200-d Avg | 31.49 | 1yr Est | 46.46 |
STOK News
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company de
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein ex
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expre
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expre
JP Morgan analyst Jessica Fye reinstates Stoke Therapeutics (NASDAQ:STOK) with a Overweight and a
Guggenheim analyst Yatin Suneja reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and mainta
Stoke Therapeutics (STOK) reported mixed Q2 results with losses of 93 cents per share and sales of $
Wedbush analyst Laura Chico maintains Stoke Therapeutics (NASDAQ:STOK) with a Outperform and rais
Canaccord Genuity analyst Sumant Kulkarni maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy a
Up to $200,000,000Common StockWe previously entered into a Controlled Equity OfferingSM Sales Agreem
Stoke Therapeutics (NASDAQ:STOK) reported quarterly losses of $(0.93) per share which missed the ana
Goldman Sachs analyst Kevin Strang initiates coverage on Stoke Therapeutics (NASDAQ:STOK) with a
—Company plans to initiate a rolling U.S. NDA submission to the FDA in the first quarter of 2027——Ph
BTIG analyst Thomas Shrader reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains
Stoke Therapeutics (NASDAQ:STOK) reported quarterly losses of $(0.79) per share which beat the analy
Wall Street analysts changed outlook on top names: Morgan Stanley raised Lemonade's PT to $85,
On Wednesday, 311 stocks hit new 52-week lows.
On Tuesday, 647 companies set new 52-week lows.
During Thursday's session, 406 companies made new 52-week lows.
On Tuesday, 386 stocks made new 52-week lows.
During the session on Thursday, 461 stocks hit new 52-week lows.
On Wednesday, 179 companies reached new 52-week lows.
During Monday's session, 201 stocks hit new 52-week lows.
Wednesday saw 59 companies set new 52-week lows.
Gainers Aurora Acquisition Corp. (NASDAQ: AURC) shares jumped 192% to $30.54.
On Tuesday, 56 companies set new 52-week lows.
Gainers Tupperware Brands Corporation (NYSE: TUP) shares jumped 59% to $1.43 on above-average vo
U.S. stocks traded higher, with the Dow Jones gaining around 90 points on Friday. Here are some big
On Friday, 72 companies hit new 52-week lows.
On Tuesday, 951 companies hit new 52-week lows.
During Monday's trading, 1214 companies set new 52-week lows.
On Wednesday, 215 companies set new 52-week lows.
On Tuesday, 540 companies set new 52-week lows.
During Wednesday's trading, 435 companies set new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
Wednesday's session saw 784 companies set new 52-week lows.
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week
On Thursday, 105 stocks hit new 52-week lows.